Long-term results of carotid stenting are competitive with surgery

• Published in: Journal of vascular surgery 2005-02, Vol.41 (2), p.213-221
• Main Authors: Bergeron, Patrice, Roux, Michel, Khanoyan, Patrick, Douillez, Valérie, Bras, Jacques, Gay, Joël
• Format: Article
• Language: English
• Subjects: Adult; Aged; Angioplasty - methods; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation - methods; Carotid Stenosis - surgery; Endarterectomy, Carotid - methods; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Stents; Stroke - prevention & control; Time Factors
• ISSN: 0741-5214; 1097-6809
• DOI: 10.1016/j.jvs.2004.11.037

The feasibility of carotid stenting (CS) is no longer questionable, although its indications remain debatable. Until the results of randomized trials are available, personal series and registries should help in the comparison of long-term results of CS with those of endarterectomy. We report here the long-term results of a large series of CS in our department with a long follow-up. This retrospective study reviews a single surgeon’s 11-year experience with CS. Our results are compared with those of conventional surgery emanating from our own series and the North American Symptomatic Carotid Endarterectomy Trial (NASCET), European Carotid Surgery Trial (ECST), and Asymptomatic Carotid Atherosclerosis Study (ACAS). CS has been performed in our department in a single, semi-private institution for 12 years. Patients with high lesions, and postradiotherapy and postendarterectomy stenoses were treated with CS, as were patients at high risk for surgery. The others were operated on with conventional endarterectomy. During the study, we performed 221 CS procedures on 193 patients (150 men and 43 women). The average follow-up was 2.7 years (1 month to 9.3 years). We analyzed the late results in terms of prevention from stroke, the freedom from new neurologic events, and also patency rates of the treated carotid vessels. We also identified predictors for neurologic complication and in-stent restenosis by using univariate analysis. Life-table analyses at 10 years gave a 96% (confidence interval [CI] = 3%) rate for stroke freedom, a 98% (CI = 2%) rate for fatal stroke freedom, and a primary assisted patency rate of 95% (CI = 3%). Predictors for neurologic complication were male sex ( P = .008) and age >70 ( P = .04), potential renal insufficiency ( P = .055), location of the lesion at the bifurcation ( P = .031), femoral access site ( P = .010), use of cerebral protection ( P = .022), and self-expandable stents ( P = .030). In-stent restenosis occurrence extended from 2 months to 4.5 years after the procedure. The restenosis rates at 6 months, 1, 2, and 4.5 years were, respectively, 1.4%, 2.3%, 3.7%, and 5.9% (13/221). Asymptomatic lesions ( P = .039) and the use of balloon-expandable stents ( P = .055) were found to be predictors of in-stent restenosis. These long-term results show that CS is competitive with conventional surgery. A more accurate selection for CS or surgery might reduce the rate of complications after carotid stenosis repair.